ACM
TSHA icon

Aquatic Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Aquatic Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$737K Buy
108,208
+68,352
+171% +$404K 0.03% 654
2026
Q1 		$178K Buy
+39,856
New +$185K 0.01% 1012
2025
Q1 		– Sell
-78,246
Closed -$135K – 1640
2024
Q4 		$135K Buy
+78,246
New +$162K ﹤0.01% 1013
2024
Q2 		– Sell
-400
Closed -$1.15K – 1605
2024
Q1 		$1.15K Buy
+400
New +$834 ﹤0.01% 1173

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aquatic Capital Management's TSHA Position: Q2 2026 in Review

Aquatic Capital Management increased its Taysha Gene Therapies (TSHA) stake by 171% in Q2 2026, buying an estimated $404K and bringing the position to 108,208 shares worth $737K. The position accounts for 0.03% of the portfolio, ranked #654.

Aquatic Capital Management first reported a position in TSHA in Q1 2024 and has held it in 4 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Aquatic Capital Management held 108,208 shares of Taysha Gene Therapies worth $737K as of Q2 2026.
  • Aquatic Capital Management bought 68,352 Taysha Gene Therapies shares in Q2 2026, an estimated $404K.
  • Taysha Gene Therapies made up 0.03% of Aquatic Capital Management's portfolio in Q2 2026, its #654 holding.
  • Aquatic Capital Management first reported a position in Taysha Gene Therapies in Q1 2024 and has held it in 4 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.